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To the Editor:
We read with great interest the arti-
cle by Osarogiagbon et al.1 highlighting 
the role of accurate mediastinal staging 
of resected non–small-cell lung cancer 
(NSCLC). New surgical approaches have 
been proposed in the recent years in case 
of cT1a, N0, or N1 less than hilar NSCLC. 
These include sublobar resection, video-
assisted lobectomy, and robotic lobec-
tomy. Moreover, new lymphadenectomy 
approaches have been proposed and 
adopted in early-stage NSCLC, including 
lobe-specific lymphadenectomy in cT1a 
as proposed in Europe by the European 
Society of Thoracic Surgeons (ESTS) 
guidelines,2 and lymph node sampling 
according to the American College of 
Surgery Oncology Group Trial proposed 
by Darling et al.3 In early-stage NSCLC 
(clinically N0 with pathological nodule 
size ≤10 mm), systematic nodal dissec-
tion seems to be universally unnecessary 
as the risk of nodal involvement is very 
low. In this scenario, the patients selec-
tion for sublobar or lobar resection and 
the role of mediastinal sampling versus 
radical lymphadenectomy is actually cru-
cial because of the increasing proportion 
of lung cancer screening programs, and 
because of the new implications of the 
International Association for the Study of 
Lung Cancer/American Thoracic Society/
European Respiratory Society revision 
of the adenocarcinoma classification.4 
These could have profound implications 
for thoracic surgeons. Indeed, as reported 
by Van Schill et al.5 the new categories, 
adenocarcinoma in situ (AIS) and mini-
mally invasive adenocarcinoma (MIA) 
less than 3 cm, should have 100% 5-year 
disease-free survival after sublobar resec-
tion and mediastinal sampling. The defi-
nitions of AIS and MIA seem to overlap 
almost precisely with the kinds of small, 
less-aggressive tumors identified by the 
clinical evidence, like ground-glass opac-
ity (GGO). We completely agree with 
the Osarogiagbon et al.that most resec-
tions had suboptimal mediastinal lymph 
node examination up to 40%, according 
to Surveillance, Epidemiology and End 
Results and National Non-Communicable 
Diseases Program data sets, but maybe in 
a cT1 GGO-adenocarcinoma subset, the 
complete mediastinal lymph node exami-
nation (CMLE) may not be necessary. The 
analysis of the correlation among GGO, 
AIS/MIA histology, and limited resection 
without CMLE could strengthen the sur-
gical implications of the new adenocarci-
noma classification. In the near future, the 
role of the multidisciplinary team will be 
crucial in defining pre- and intraoperative 
early-stage AIS or MIA, and in tailoring 
and planning oncologically valid limited 
resections without CMLE.
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In Response:
Cafarotti et al.1 raise several ques-
tions about the optimal surgical lymph 
node staging procedure in patients with 
relatively low-risk non–small-cell lung 
cancer, especially adenocarcinoma in 
situ and minimally invasive adeno-
carcinoma. Their departure point was 
a report in this journal, of poor cor-
relation between surgical mediastinal 
lymph node examination claims and an 
audit of lymph nodes identified in the 
pathology report.2
The roles of minimally invasive 
lung resection and sublobar resection 
are not addressed in the reference pub-
lication.2 But neither the technique of 
resection (open, video-assisted, robotic-
assisted), nor the extent of resection 
(wedge, segmental, lobar, or more 
extensive) alter the need for an onco-
logically sound operation with nega-
tive margins and proper nodal staging. 
Until the results of the ongoing North 
American (Cancer and Leukemia 
Group B 140503 [ClinicalTrials.gov 
#00499330]) and Japanese (Japan 
Clinical Oncology Group 0802/West 
Japan Oncology Group 4607L) trials 
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